Quetiapine extended release for the treatment of bipolar disorder

References

• Elgie R, Morselli PL. Social functioning in bipolar patients: the perception and perspective of patients, relatives and advocacy organizations - a review. Bipolar Disord 2007;9(1-2):144-57
   PubMedGoogle Scholar
• Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003;73(1-2):123-31
   PubMed Web of Science ®Google Scholar
• Pini S, de Queiroz V, Pagnin D, et al. Prevalence and burden of bipolar disorders in European countries. Eur Neuropsychopharmacol 2005;15(4):425-34
   PubMed Web of Science ®Google Scholar
• Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: global Burden of Disease Study. Lancet 1997;349(9063):1436-42
   PubMed Web of Science ®Google Scholar
• Frye MA, Ha K, Kanba S, et al. International consensus group on depression prevention in bipolar disorder. J Clin Psychiatry 2011;72(10):1295-310
   PubMedGoogle Scholar
• Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009;23(4):346-88
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009;10(2):85-116
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010;11(2):81-109
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 2013;14(3):154-219
   PubMed Web of Science ®Google Scholar
• Llorca PM, Courtet P, Martin P, et al. Screening and management of bipolar disorders: results. Encephale 2010;36(Suppl 4):S86-102
   PubMedGoogle Scholar
• Malhi GS, Adams D, Lampe L, et al. Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand Suppl 2009;(439):27-46
   PubMedGoogle Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013;15(1):1-44
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Kasper S, Johnson G, et al. International consensus group on bipolar i depression treatment guidelines. J Clin Psychiatry 2004;65(4):571-9
   PubMedGoogle Scholar
• Samalin L, Guillaume S, Courtet P, et al. Methodological differences between pharmacological treatment guidelines for bipolar disorder: what to do for the clinicians? Compr Psychiatry 2013;54(4):309-20
   PubMedGoogle Scholar
• El-Khalili N. Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders. Neuropsychiatr Dis Treat 2012;8:523-36
   PubMed Web of Science ®Google Scholar
• Sanford M, Keating GM. Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs 2012;26(5):435-60
   PubMedGoogle Scholar
• AstraZeneca. Seroquel® (quetiapine fumarate) tablets: highlights of prescribing information. 2011. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2011/020639s049s054lbl.pdf
   Google Scholar
• AstraZeneca. Seroquel® (quetiapine): summary of product characteristics. 2012. Available from: www.medicines.org.uk/emc/medicine/2295
   Google Scholar
• Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005;66(1):111-21
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania - a 12-week, double-blind, randomized, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005;15(5):573-85
   PubMed Web of Science ®Google Scholar
• Vieta E, Mullen J, Brecher M, et al. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomized, placebo-controlled studies. Curr Med Res Opin 2005;21(6):923-34
   PubMed Web of Science ®Google Scholar
• Pathak S, Findling RL, Earley WR, et al. Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial. J Clin Psychiatry 2013;74(1):100-9
   PubMed Web of Science ®Google Scholar
• Sachs G, Chengappa KN, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004;6(3):213-23
   PubMed Web of Science ®Google Scholar
• Yatham LN, Vieta E, Young AH, et al. A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania. Int Clin Psychopharmacol 2007;22(4):212-20
   PubMed Web of Science ®Google Scholar
• Yatham LN, Paulsson B, Mullen J, Vågerö M. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol 2004;24(6):599-606
   PubMedGoogle Scholar
• Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162(7):1351-60
   PubMed Web of Science ®Google Scholar
• Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006;26(6):600-9
   PubMed Web of Science ®Google Scholar
• Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010;71(2):150-62
   PubMed Web of Science ®Google Scholar
• McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010;71(2):163-74
   PubMed Web of Science ®Google Scholar
• Vieta E, Suppes T, Eggens I, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008;109(3):251-63
   PubMed Web of Science ®Google Scholar
• Suppes T, Vieta E, Liu S, et al. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009;166(4):476-88
   PubMed Web of Science ®Google Scholar
• Ketter TA, Citrome L, Wang PW, et al. Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? Acta Psychiatr Scand 2011;123(3):175-89
   PubMed Web of Science ®Google Scholar
• Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract 2013;67(5):407-11
   PubMed Web of Science ®Google Scholar
• Citrome L, Ketter TA, Cucchiaro J, Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord 2014;155:20-7
   PubMed Web of Science ®Google Scholar
• Citrome L. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf 2009;4(3):229-37
   PubMedGoogle Scholar
• AstraZeneca. Seroquel XR® (quetiapine fumarate) extended-release tablets : highlights of prescribing information. 2009. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2009/022047s011s016s017s019s022lbl.pdf
   Google Scholar
• AstraZeneca. Seroquel XL® (quetiapine) prolonged-release tablets: summary of product characteristics. 2012. Available from: www.medicines.org.uk/emc/medicine/21175/SPC/Seroquel+XL+50+mg%2c+150mg%2c+200+mg%2c+300+mg%2c+400+mg+prolonged-release+tablets/
   Google Scholar
• Bui K, Earley W, Nyberg S. Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications. Curr Med Res Opin 2013;29(7):813-25
   PubMed Web of Science ®Google Scholar
• Figueroa C, Brecher M, Hamer-Maansson JE, Winter H. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009;33(2):199-204
   PubMed Web of Science ®Google Scholar
• Goldstein J, Christoph G, Grimm S, et al. Quetiapine’s antidepressant properties: direct and indirect pharmacologic actions on norepinephrine and serotonin receptors. Eur Neuropsychopharmacol 2007;17(Suppl 4):S401
   Web of Science ®Google Scholar
• Nyberg S, Jucaite A, Takano A, et al. Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR. Int J Neuropsychopharmacol 2013;16(10):2235-44
   PubMed Web of Science ®Google Scholar
• Bjorkholm C, Jardemark K, Marcus MM, et al. Role of concomitant inhibition of the norepinephrine transporter for the antipsychotic effect of quetiapine. Eur Neuropsychopharmacol 2013;23(7):709-20
   PubMed Web of Science ®Google Scholar
• Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine re-uptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology 2008;33(10):2303-12
   PubMed Web of Science ®Google Scholar
• Mamo DC, Uchida H, Vitcu I, et al. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry 2008;69(1):81-6
   PubMedGoogle Scholar
• Nord M, Nyberg S, Brogren J, et al. 2) dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects. Int J Neuropsychopharmacol 2011;14(10):1357-66
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Datto C, Nordenhem A, et al. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial. Clin Ther 2011;33(11):1643-58
   PubMed Web of Science ®Google Scholar
• Dell’Osso B, Arici C, Dobrea C, et al. Efficacy, tolerability, compliance, and quality of life of patients with mood disorders switched from quetiapine immediate release to extended release. Int Clin Psychopharmacol 2012;27(6):310-13
   PubMedGoogle Scholar
• Sheehan DV, Harnett-Sheehan K, Hidalgo RB, et al. Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. J Affect Disord 2013;145(1):83-94
   PubMedGoogle Scholar
• Suppes T, Datto C, Minkwitz M, et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 2010;121(1-2):106-15
   PubMed Web of Science ®Google Scholar
• AstraZeneca. NCT00521365 : effectiveness of quetiapine XR on the control of symptoms of manic phase of bipolar disorder (EMMY). 2012. Available from: www.clinicaltrials.gov/ct2/show/NCT00521365
   Google Scholar
• AstraZeneca. NCT00931723 : adult bipolar mania. 2012. Available from: www.clinicaltrials.gov/ct2/show/NCT00931723
   Google Scholar
• AstraZeneca. NCT00811473 : pediatric bipolar depression. 2012. Available from: www.clinicaltrials.gov/ct2/show/NCT00811473
   Google Scholar
• Alfaro C. An 8-week, multicenter, double-blind, randomized, parallel-group, placebo-controlled study of the efficacy and safety of quetiapine fumarate (Seroquel XR) extended-release in children and adolescent subjects with bipolar depression: clinical review. 2013. Available from: www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM358780.pdf
   Google Scholar
• AstraZeneca. NCT00883493 : efficacy and safety of quetiapine versus quetiapine plus lithium in bipolar depression (QUALITY). 2012. Available from: www.clinicaltrials.gov/ct2/show/NCT00883493
   Google Scholar
• AstraZeneca. NCT00857584: quetiapine XR versus sertraline in acute bipolar depression as add-on therapy. 2012. Available from: www.clinicaltrials.gov/ct2/show/NCT00857584
   Google Scholar
• Gao K. NCT00671853 : quetiapine extended release (XR) in bipolar patients with comorbid generalized anxiety disorder (GAD). 2013. Available from: www.clinicaltrials.gov/ct2/show/NCT00671853
   Google Scholar
• DelBello MP, Chang K, Welge JA, et al. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 2009;11(5):483-93
   PubMed Web of Science ®Google Scholar
• Weisler RH, Calabrese JR, Thase ME, et al. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 2008;69(5):769-82
   PubMed Web of Science ®Google Scholar
• Suppes T, Hirschfeld RM, Vieta E, et al. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry 2008;9(3):198-211
   PubMed Web of Science ®Google Scholar
• Young AH, Calabrese JR, Gustafsson U, et al. Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. Int J Bipolar Disord 2013;1(1):1-12
   PubMedGoogle Scholar
• Datto C, Berggren L, Patel JB, Eriksson H. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clin Ther 2009;31(3):492-502
   PubMed Web of Science ®Google Scholar
• Riesenberg RA, Baldytcheva I, Datto C. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study. Clin Ther 2012;34(11):2202-11
   PubMedGoogle Scholar
• Meulien D, Huizar K, Brecher M. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol 2010;25(2):103-15
   PubMedGoogle Scholar
• Peuskens J, Trivedi J, Malyarov S, et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients. Psychiatry (Edgmont) 2007;4(11):34-50
   PubMedGoogle Scholar
• Wang Z, Kemp DE, Chan PK, et al. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder. Int J Neuropsychopharmacol 2011;14(1):131-42
   PubMed Web of Science ®Google Scholar
• Peuskens J. The management of schizophrenia: focus on extended-release quetiapine fumarate. Neuropsychiatr Dis Treat 2011;7:549-64
   PubMed Web of Science ®Google Scholar
• Lang K, Korn J, Muser E, et al. Predictors of medication nonadherence and hospitalization in Medicaid patients with bipolar I disorder given long-acting or oral antipsychotics. J Med Econ 2011;14(2):217-26
   PubMedGoogle Scholar
• Gao K, Kemp DE, Fein E, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry 2011;72(8):1063-71
   PubMed Web of Science ®Google Scholar
• Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261(22):3273-7
   PubMed Web of Science ®Google Scholar
• Gutierrez-Rojas L, Jurado D, Martinez-Ortega JM, Gurpegui M. Poor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sample. J Affect Disord 2010;127(1-3):77-83
   PubMedGoogle Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23(8):1296-310
   PubMed Web of Science ®Google Scholar
• Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009;166(2):152-63
   PubMed Web of Science ®Google Scholar
• Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010;123(2-3):225-33
   PubMed Web of Science ®Google Scholar
• Wang M, Tong JH, Huang DS, et al. Efficacy of olanzapine monotherapy for treatment of bipolar I depression: a randomized, double-blind, placebo controlled study. Psychopharmacology (Berl) 2014;231(14):2811-18
   PubMed Web of Science ®Google Scholar
• Tohen M, Katagiri H, Fujikoshi S, Kanba S. Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies. J Affect Disord 2013;149(1-3):196-201
   PubMed Web of Science ®Google Scholar
• Cerullo MA, Strakowski SM. A systematic review of the evidence for the treatment of acute depression in bipolar I disorder. CNS Spectr 2013;18(4):199-208
   PubMedGoogle Scholar
• Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomized trials. Br J Psychiatry 2009;194(1):4-9
   PubMed Web of Science ®Google Scholar
• Bond DJ, Lam RW, Yatham LN. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J affect disord 2010;124:228-34
   PubMed Web of Science ®Google Scholar
• Geoffroy PA, Bellivier F, Leboyer M, Etain B. Can the response to mood stabilizers be predicted in bipolar disorder? Front Biosci (Elite Ed) 2014;6:120-38
   PubMedGoogle Scholar
• Murphy E, McMahon FJ. Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations. Discov Med 2013;16(87):113-22
   PubMed Web of Science ®Google Scholar